Pharmicell Co., Ltd. (KRX:005690)
South Korea flag South Korea · Delayed Price · Currency is KRW
11,570
+140 (1.22%)
At close: Mar 24, 2025, 3:30 PM KST

Pharmicell Statistics

Total Valuation

Pharmicell has a market cap or net worth of KRW 612.64 billion.

Market Cap 612.64B
Enterprise Value n/a

Important Dates

Earnings Date n/a
Ex-Dividend Date Dec 27, 2024

Share Statistics

Pharmicell has 60.00 million shares outstanding.

Current Share Class n/a
Shares Outstanding 60.00M
Shares Change (YoY) n/a
Shares Change (QoQ) +1.98%
Owned by Insiders (%) 9.34%
Owned by Institutions (%) 9.12%
Float 54.21M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 18.61
PB Ratio 5.47
P/TBV Ratio 12.37
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.14.

Current Ratio 1.34
Quick Ratio 1.05
Debt / Equity 0.14
Debt / EBITDA n/a
Debt / FCF -1.50
Interest Coverage -7.48

Financial Efficiency

Return on equity (ROE) is -29.25% and return on invested capital (ROIC) is -5.33%.

Return on Equity (ROE) -29.25%
Return on Assets (ROA) -4.98%
Return on Invested Capital (ROIC) -5.33%
Return on Capital Employed (ROCE) -10.54%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover 0.21
Inventory Turnover 5.05

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +80.50% in the last 52 weeks. The beta is -1.39, so Pharmicell's price volatility has been lower than the market average.

Beta (5Y) -1.39
52-Week Price Change +80.50%
50-Day Moving Average 10,184.00
200-Day Moving Average 6,882.10
Relative Strength Index (RSI) 43.29
Average Volume (20 Days) 1,848,905

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Pharmicell had revenue of KRW 23.94 billion and -26.78 billion in losses. Loss per share was -613.75.

Revenue 23.94B
Gross Profit 5.45B
Operating Income -9.29B
Pretax Income -26.75B
Net Income -26.78B
EBITDA -6.18B
EBIT -9.29B
Loss Per Share -613.75
Full Income Statement

Balance Sheet

The company has 9.44 billion in cash and 11.74 billion in debt, giving a net cash position of -2.30 billion or -38.34 per share.

Cash & Cash Equivalents 9.44B
Total Debt 11.74B
Net Cash -2.30B
Net Cash Per Share -38.34
Equity (Book Value) 84.27B
Book Value Per Share 1,867.90
Working Capital 4.72B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.55 billion and capital expenditures -272.69 million, giving a free cash flow of -7.82 billion.

Operating Cash Flow -7.55B
Capital Expenditures -272.69M
Free Cash Flow -7.82B
FCF Per Share -130.32
Full Cash Flow Statement

Margins

Gross margin is 22.74%, with operating and profit margins of -38.80% and -111.85%.

Gross Margin 22.74%
Operating Margin -38.80%
Pretax Margin -111.71%
Profit Margin -111.85%
EBITDA Margin -25.83%
EBIT Margin -38.80%
FCF Margin n/a

Dividends & Yields

This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.17%.

Dividend Per Share 20.00
Dividend Yield 0.17%
Dividend Growth (YoY) n/a
Years of Dividend Growth 1
Payout Ratio n/a
Buyback Yield -7.56%
Shareholder Yield -7.39%
Earnings Yield -4.37%
FCF Yield -1.28%
Dividend Details

Stock Splits

The last stock split was on December 1, 2011. It was a forward split with a ratio of 10.

Last Split Date Dec 1, 2011
Split Type Forward
Split Ratio 10

Scores

Pharmicell has an Altman Z-Score of 4.6.

Altman Z-Score 4.6
Piotroski F-Score n/a